Finanzen von Iambic Therapeutics, Inc. Common Stock (IAM)IAMIambic Therapeutics, Inc. Common Stock

In the context of the broader market, IAM competes directly with industry leaders such as PRME and SANA. With a market capitalization of $700.58M, it holds a significant position in the sector. When comparing efficiency, IAM's gross margin of N/A stands against PRME's 100.00% and SANA's N/A. Such benchmarking helps identify whether Iambic Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

The company shows no earnings with a P/E ratio of 0 and a forward P/E of 0, indicating it is not generating profits. Its price-to-sales ratio is quite high at 38.1, which raises concerns about valuation.